{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T00:01:01Z","timestamp":1792022461970,"version":"4.4.0"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2024,4,29]],"date-time":"2024-04-29T00:00:00Z","timestamp":1714348800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,4,29]],"date-time":"2024-04-29T00:00:00Z","timestamp":1714348800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["21K06696"],"award-info":[{"award-number":["21K06696"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Drug Investig"],"published-print":{"date-parts":[[2024,5]]},"DOI":"10.1007\/s40261-024-01361-3","type":"journal-article","created":{"date-parts":[[2024,4,29]],"date-time":"2024-04-29T17:01:51Z","timestamp":1714410111000},"page":"357-366","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Prediction Model for Severe Thrombocytopenia Induced by Gemcitabine Plus Cisplatin Combination Therapy in Patients with Urothelial Cancer"],"prefix":"10.1007","volume":"44","author":[{"given":"Noriaki","family":"Matsumoto","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8203-392X","authenticated-orcid":false,"given":"Tomohiro","family":"Mizuno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yosuke","family":"Ando","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koki","family":"Kato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masanori","family":"Nakanishi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tsuyoshi","family":"Nakai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeannie K.","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshitaka","family":"Kameya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wataru","family":"Nakamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kiyoshi","family":"Takahara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryoichi","family":"Shiroki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shigeki","family":"Yamada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,4,29]]},"reference":[{"issue":"17","key":"1361_CR1","doi-asserted-by":"publisher","first-page":"3068","DOI":"10.1200\/JCO.2000.18.17.3068","volume":"18","author":"H von der Maase","year":"2000","unstructured":"von der Maase H, Hansen SW, Roberts JT, Dogliotti L, Oliver T, Moore MJ, et al. Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study. J Clin Oncol. 2000;18(17):3068\u201377.","journal-title":"J Clin Oncol"},{"issue":"2","key":"1361_CR2","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1182\/blood.V92.2.405","volume":"92","author":"JY Blay","year":"1998","unstructured":"Blay JY, Le Cesne A, Mermet C, Maugard C, Ravaud A, Chevreau C, et al. A risk model for thrombocytopenia requiring platelet transfusion after cytotoxic chemotherapy. Blood. 1998;92(2):405\u201310.","journal-title":"Blood"},{"issue":"Suppl","key":"1361_CR3","first-page":"S656","volume":"14","author":"Z Wang","year":"2018","unstructured":"Wang Z, Cai XJ, Chen LY, Cheng B, Shi L, Lei L, et al. Factors potentially associated with gemcitabine-based chemotherapy-induced thrombocytopenia in Chinese patients with nonsmall cell lung cancer. J Cancer Res Ther. 2018;14(Suppl):S656\u201360.","journal-title":"J Cancer Res Ther"},{"issue":"1\u20132","key":"1361_CR4","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1159\/000508805","volume":"65","author":"N Takahashi","year":"2020","unstructured":"Takahashi N, Sunaga T, Fujimiya T, Kurihara T, Nagatani A, Yamagishi M, et al. Risk associated with severe hematological toxicity in patients with urothelial cancer receiving combination chemotherapy of gemcitabine and cisplatin. Chemotherapy. 2020;65(1\u20132):29\u201334.","journal-title":"Chemotherapy"},{"issue":"11","key":"1361_CR5","doi-asserted-by":"publisher","first-page":"5729","DOI":"10.21873\/anticanres.15389","volume":"41","author":"M Takahashi","year":"2021","unstructured":"Takahashi M, Takahashi K, Kaneda H, Kawaguchi T, Nagayama K. Pretreatment platelet count and neutrophil\/lymphocyte ratio are predictive markers for carboplatin plus pemetrexed therapy-induced thrombocytopenia. Anticancer Res. 2021;41(11):5729\u201337.","journal-title":"Anticancer Res"},{"issue":"1","key":"1361_CR6","doi-asserted-by":"publisher","first-page":"3185","DOI":"10.1038\/s41598-023-27824-9","volume":"13","author":"S Zhou","year":"2023","unstructured":"Zhou S, Song B, Li C, Tang W, Zhang X, Jin X, et al. The predictive model for risk of chemotherapy-induced thrombocytopenia based on antineoplastic drugs for solid tumors in eastern China. Sci Rep. 2023;13(1):3185.","journal-title":"Sci Rep"},{"issue":"1","key":"1361_CR7","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0262021","volume":"17","author":"T Okawa","year":"2022","unstructured":"Okawa T, Mizuno T, Hanabusa S, Ikeda T, Mizokami F, Koseki T, et al. Prediction model of acute kidney injury induced by cisplatin in older adults using a machine learning algorithm. PLoS ONE. 2022;17(1): e0262021.","journal-title":"PLoS ONE"},{"issue":"1","key":"1361_CR8","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1111\/biom.12107","volume":"70","author":"LE Bantis","year":"2014","unstructured":"Bantis LE, Nakas CT, Reiser B. Construction of confidence regions in the ROC space after the estimation of the optimal Youden index-based cut-off point. Biometrics. 2014;70(1):212\u201323.","journal-title":"Biometrics"},{"issue":"3","key":"1361_CR9","doi-asserted-by":"publisher","first-page":"837","DOI":"10.2307\/2531595","volume":"44","author":"ER DeLong","year":"1988","unstructured":"DeLong ER, DeLong DM, Clarke-Pearson DL. Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. Biometrics. 1988;44(3):837\u201345.","journal-title":"Biometrics"},{"issue":"3","key":"1361_CR10","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1038\/bmt.2012.244","volume":"48","author":"Y Kanda","year":"2013","unstructured":"Kanda Y. Investigation of the freely available easy-to-use software \u201cEZR\u201d for medical statistics. Bone Marrow Transplant. 2013;48(3):452\u20138.","journal-title":"Bone Marrow Transplant"},{"key":"1361_CR11","unstructured":"Sony Network Communications, Inc. Prediction One [cited 22 Mar 2024]. https:\/\/predictionone.sony.biz\/."},{"key":"1361_CR12","volume-title":"Evaluating learning algorithms: a classification perspective","author":"J Nathalie","year":"2011","unstructured":"Nathalie J, Mohak S. Evaluating learning algorithms: a classification perspective. Cambridge: Cambridge University Press; 2011."},{"key":"1361_CR13","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.g7594","volume":"350","author":"GS Collins","year":"2015","unstructured":"Collins GS, Reitsma JB, Altman DG, Moons KG. Transparent reporting of a multivariable prediction model for individual prognosis or diagnosis (TRIPOD): the TRIPOD statement. BMJ. 2015;350: g7594.","journal-title":"BMJ"},{"issue":"1","key":"1361_CR14","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1159\/000326801","volume":"4","author":"PM Kasi","year":"2011","unstructured":"Kasi PM. Thrombotic thrombocytopenic purpura and gemcitabine. Case Rep Oncol. 2011;4(1):143\u20138.","journal-title":"Case Rep Oncol"},{"issue":"11","key":"1361_CR15","doi-asserted-by":"publisher","first-page":"1553","DOI":"10.1023\/A:1013133415945","volume":"12","author":"S Fogli","year":"2001","unstructured":"Fogli S, Danesi R, De Braud F, De Pas T, Curigliano G, Giovannetti G, et al. Drug distribution and pharmacokinetic\/pharmacodynamic relationship of paclitaxel and gemcitabine in patients with non-small-cell lung cancer. Ann Oncol. 2001;12(11):1553\u20139.","journal-title":"Ann Oncol"},{"issue":"8","key":"1361_CR16","doi-asserted-by":"publisher","first-page":"1618","DOI":"10.1200\/JCO.22.00763","volume":"41","author":"JA Coleman","year":"2023","unstructured":"Coleman JA, Yip W, Wong NC, Sjoberg DD, Bochner BH, Dalbagni G, et al. Multicenter phase II clinical trial of gemcitabine and cisplatin as neoadjuvant chemotherapy for patients with high-grade upper tract urothelial carcinoma. J Clin Oncol. 2023;41(8):1618\u201325.","journal-title":"J Clin Oncol"},{"key":"1361_CR17","doi-asserted-by":"publisher","first-page":"8003","DOI":"10.2147\/IJGM.S383349","volume":"15","author":"B Song","year":"2022","unstructured":"Song B, Zhou S, Li C, Zheng H, Zhang X, Jin X, et al. A prediction model for chemotherapy-induced thrombocytopenia based on real-world data and a close relationship between AST\/ALT ratio and platelet count in patients with solid tumors. Int J Gen Med. 2022;15:8003\u201315.","journal-title":"Int J Gen Med."},{"key":"1361_CR18","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/j.lungcan.2019.08.018","volume":"136","author":"Y Suzuki","year":"2019","unstructured":"Suzuki Y, Kanazawa K, Kanai R, Tomita H, Saito M, Watanabe N, et al. A case of primary lung squamous cell carcinoma mimicking malignant mesothelioma producing granulocyte colony stimulating factor with chemotherapy (cisplatin and gemcitabine)-associated thrombotic thrombocytopenic purpura (TTP); an autopsy case report. Lung Cancer. 2019;136:105\u20138.","journal-title":"Lung Cancer"},{"issue":"10","key":"1361_CR19","doi-asserted-by":"publisher","first-page":"1111","DOI":"10.2169\/internalmedicine.52.9180","volume":"52","author":"Y Nishijima","year":"2013","unstructured":"Nishijima Y, Hirata H, Himeno A, Kida H, Matsumoto M, Takahashi R, et al. Drug-induced thrombotic thrombocytopenic purpura successfully treated with recombinant human soluble thrombomodulin. Intern Med. 2013;52(10):1111\u20134.","journal-title":"Intern Med"},{"issue":"6","key":"1361_CR20","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1007\/s11096-014-0032-9","volume":"36","author":"I Alabiso","year":"2014","unstructured":"Alabiso I, Baratelli C, Brizzi MP, Bitossi R, Ottone A, Tampellini M. Acute and fatal thrombocytopenic thrombotic purpura after a single dose of pemetrexed. Int J Clin Pharm. 2014;36(6):1141\u20133.","journal-title":"Int J Clin Pharm"},{"issue":"9","key":"1361_CR21","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1016\/S1470-2045(07)70253-X","volume":"8","author":"J Thachil","year":"2007","unstructured":"Thachil J. Causes of thrombotic thrombocytopenic purpura. Lancet Oncol. 2007;8(9):757\u20138.","journal-title":"Lancet Oncol"},{"issue":"11","key":"1361_CR22","doi-asserted-by":"publisher","first-page":"2192","DOI":"10.1200\/JCO.2003.08.046","volume":"21","author":"BC Kuenen","year":"2003","unstructured":"Kuenen BC, Levi M, Meijers JC, van Hinsbergh VW, Berkhof J, Kakkar AK, et al. Potential role of platelets in endothelial damage observed during treatment with cisplatin, gemcitabine, and the angiogenesis inhibitor SU5416. J Clin Oncol. 2003;21(11):2192\u20138.","journal-title":"J Clin Oncol"},{"issue":"7","key":"1361_CR23","doi-asserted-by":"publisher","first-page":"634","DOI":"10.1016\/S1470-2045(07)70203-6","volume":"8","author":"M Zupancic","year":"2007","unstructured":"Zupancic M, Shah PC, Shah-Khan F. Gemcitabine-associated thrombotic thrombocytopenic purpura. Lancet Oncol. 2007;8(7):634\u201341.","journal-title":"Lancet Oncol"}],"container-title":["Clinical Drug Investigation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40261-024-01361-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40261-024-01361-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40261-024-01361-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,11]],"date-time":"2024-05-11T05:35:33Z","timestamp":1715405733000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40261-024-01361-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,29]]},"references-count":23,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2024,5]]}},"alternative-id":["1361"],"URL":"https:\/\/doi.org\/10.1007\/s40261-024-01361-3","relation":{},"ISSN":["1173-2563","1179-1918"],"issn-type":[{"value":"1173-2563","type":"print"},{"value":"1179-1918","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,4,29]]},"assertion":[{"value":"14 April 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 April 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Shigeki Yamada has received honoraria from Nippon Shinyaku Co., Ltd, Pfizer Japan Inc., and Takeda Pharmaceutical Co., Ltd. Tomohiro Mizuno is an editorial board member of <i>Clinical Drug Investigation<\/i>. Noriaki Matsumoto, Yosuke Ando, Koki Kato, Masanori Nakanishi, Tsuyoshi Nakai, Jeannie K. Lee, Yoshitaka Kameya, Wataru Nakamura, Kiyoshi Takahara, and Ryoichi Shiroki declare no conflicts of interest regarding the subject of this study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This study was approved by the Ethics Board of Fujita Health University Hospital (Ethics Committee approval number: HM23-027; date of approval 9 May 2023) and was conducted in accordance with the appropriate guidelines.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"An opt-out approach was used to obtain informed consent according to the guidelines of the Fujita Health University Hospital Ethics Board.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participants"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"NM contributed to the study conception and design and drafted the manuscript. NM, KK, MN, and TN analyzed and interpreted the data. YA, JKL, YK, WN, KT, RS, and SY contributed to the study design and reviewed the manuscript. TM contributed to the study conception and design, drafted the manuscript, and supervised the execution of the study.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}},{"value":"Data archiving is not mandated but data will be made available on reasonable request.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data availability statement"}},{"value":"This work was supported by the JSPS KAKENHI (grant number 21K06696) and the Research Center for Pathogenesis of Intractable Diseases, Research Institute of Meijo University, Japan.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}}]}}